Drugs / VK-2019
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06789159 | Aug 2026 → Oct 2028 expected | Epstein-Barr virus infection, diffuse large B-cell lymphoma | Pierluigi Porcu | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03682055 | Apr 2019 → Jun 2020 | nasopharyngeal carcinoma | Cullinan Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04925544 | Jan 2022 → Jun 2026 overdue | nasopharyngeal carcinoma | Stanford University | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study nuvectis.com ↗
Overall, treatment resulted in 2 patients achieving partial response (unconfirmed) and 3 achieving stable disease. |
| 2024-11-14 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer nuvectis.com ↗
In eleven efficacy-evaluable patients, antitumor activity was observed with best responses including one patient with an unconfirmed partial response and six patients with stable disease, including tumor shrinkage. |
| 2024-08-29 | Nuvectis Pharma, Inc. | Regulatory Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers nuvectis.com ↗
Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA") for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. |
| 2024-03-14 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer nuvectis.com ↗
Nuvectis Pharma, Inc. (NASDAQ:NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. |
| 2023-08-17 | Nuvectis Pharma, Inc. | Regulatory Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma nuvectis.com ↗ |
| 2023-04-18 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research ("AACR") Annual Meeting nuvectis.com ↗
NXP800 demonstrated robust antitumor activity in two patient-derived xenograft ("PDX") models of cholangiocarcinoma |
| 2023-02-23 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress nuvectis.com ↗
Our poster today showed the activity of NXP800 in two xenograft models of ARID1a-mutated ovarian carcinoma, a genetically defined subset of ovarian cancer. |
| 2022-12-01 | Nuvectis Pharma, Inc. | Regulatory FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma nuvectis.com ↗
Nuvectis Pharma, Inc (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. |
| 2022-10-18 | Nuvectis Pharma, Inc. | Results Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics nuvectis.com ↗
Genetic loss of ARID1a, a component of the SWI/SNF chromatin remodelling complex, was identified as predictive of greater therapeutic responsiveness. |
| 2022-09-13 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma nuvectis.com ↗
Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control. |
| 2022-06-21 | Nuvectis Pharma, Inc. | Regulatory Nuvectis Pharma Announces FDA Clearance of IND for NXP800 nuvectis.com ↗
Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration ("FDA") cleared the Company's Investigational New Drug Application ("IND") for NXP800, which includes the Phase 1 clinical trial protocol. |
| 2022-04-11 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference nuvectis.com ↗
a wide range of human cancer cell lines showed that ARID1a loss was associated with increased sensitivity to treatment with NXP800 in ovarian, gastric, intestinal and other cancer cell lines |
All press releases naming this drug 12 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VK 2019 | “Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers” NCT04925544 ↗ |
| Action | Inhibit | “EBNA1 inhibitor” NCT03682055 ↗ |
| Modality | Small molecule | “Novel Small Molecule EBNA1 Inhibitor” NCT03682055 ↗ |
| Route | Oral | “orally administered VK-2019” NCT03682055 ↗ |